The UK biotech Vernalis plc has triggered a $3 million milestone in its collaboration with Novartis on the oncology target Hsp90.
The milestone is due following the first dosing in a Phase II proof of concept clinical trial of AUY-922, an Hsp90 inhibitor, in a range of solid tumours.
Ian Garland, CEO of Vernalis said, “We look forward to the results of the current Phase II proof of concept study which Novartis has indicated are targeted for 2010.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
Sign up for the Funding Newswire
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
